Assembly Biosciences, Inc.
Assembly Biosciences develops therapeutic candidates for viral diseases. They have several products in clinical trials: ABI-5366 for recurrent genital herpes, ABI-1179 for recurrent genital herpes, and ABI-6250 for hepatitis delta virus. They also develop ABI-4334 for hepatitis B virus and other treatments targeting transplant-related herpesviruses and HBV/HDV. The company has partnerships with Gilead Sciences and BeiGene.
Overview
Strengths
- Consistent growth: revenue has compounded at 35.3% a year over 5 years, rising in 4 of them.
- Skin in the game: insiders own 28% of the shares, aligning management with shareholders.
Weaknesses
- No sign of a competitive advantage: return on invested capital (latest 0.0%) has been below its cost of capital of 7.9% in 6 of the last 7 years.
- Our discounted cash flow model finds no value to support the current price: free cash flow is negative.
- Shareholder dilution: the share count has grown by 57.3% a year over the last three years.
- Currently loss-making: the latest fiscal year closed with a net loss.
- Unreliable cash generation: free cash flow was negative in 6 of the last 7 years.
- High leverage: net debt is 4.7x EBITDA, against a median of 0.5x for its Biotechnology peers.
Key Financial Data